Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, MI, has signed an agreement with the Cleveland Clinic to advance research targeting new HDL therapies to treat cardiovascular disease. “When Esperion was first founded, we collaborated with Cleveland Clinic in a research effort that showed for the first time that HDL can reverse atherosclerosis in acute coronary patients,” Roger Newton, Esperion president and CEO, says in a prepared statement. “When we re-established Esperion in 2008, our goal was to continue this research tradition.” Esperion is developing therapies to treat cardio-metabolic disease including therapies based on HDL, the body’s “good” cholesterol, which has been shown to play an important role in lipid management.
Author: Howard Lovy
Howard Lovy is a veteran journalist who has focused primarily on technology, science and innovation during the past decade.
In 2001, he helped launch Small Times Magazine, a nanotech publication based in Ann Arbor, MI, where he built the freelance team and worked closely with writers to set the tone and style for an emerging sector that had never before been covered from a business perspective. Lovy's work at Small Times, and on one of the first nanotechnology-themed blogs, helped him earn a reputation for making complex subjects understandable, interesting, and even entertaining for a broad audience. It also earned him the 2004 Prize in Communication from the Foresight Institute, a nanotech think tank.
In his freelance work, Lovy covers nanotechnology in addition to technological innovation in Michigan with an emphasis on efforts to survive and retool in the state's post-automotive age. Lovy's work has appeared in many publications, including Wired News, Salon.com, the Wall Street Journal, The Detroit News, The Scientist, the Forbes/Wolfe Nanotech Report, Michigan Messenger, and the Ann Arbor Chronicle.
View all posts by Howard Lovy